MODIFICATION OF THE NARCOTICS LAW TO REGULATE CANNABIDIOL'S (CBD) MEDICAL USE

Provisions in Law No. 35 of 2009 on Narcotics still classify all cannabis derivatives, including non-psychoactive CBD, as Class I narcotics, thereby legally hindering their use despite their medical benefits. This study aims to analyze the urgency of reformulating CBD regulations in the Narcotics Law, assess the suitability of current provisions with medical developments and international standards, and examine alternative regulatory models to ensure safe and controlled medical access. The findings of the study indicate that a revision of the Narcotics Law is necessary to completely separate CBD from the overall classification of cannabis, establish standards for monitoring medical use, prepare licensing mechanisms for production and distribution based on patient safety, and ensure legal protection for health workers and patients. This reformulation is expected to create a balance between drug control and the fulfillment of the right to health through the responsible use of CBD for therapeutic purposes.